To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Decline of C-peptide duri… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents.

Journal article
Authors Johnny Ludvigsson
Annelie Carlsson
Ahmed Deli
Gun Forsander
Sten-A Ivarsson
Ingrid Kockum
Bengt Lindblad
Claude Marcus
Ake Lernmark
Ulf Samuelsson
Published in Diabetes research and clinical practice
Volume 100
Issue 2
Pages 203–209
ISSN 1872-8227
Publication year 2013
Published at
Pages 203–209
Language en
Keywords C-peptide; Natural course; Type 1 diabetes; Children; BMI; Intervention trials
Subject categories Pediatrics

Abstract

AIMS/HYPOTHESIS: We studied the decline of C-peptide during the first year after diagnosis of Type 1 diabetes (T1D), and its relation to various factors. METHODS: 3824/4017 newly diagnosed patients (95%) were classified as T1D in a national study. In a non-selected subgroup of 1669 T1D patients we determined non-fasting C-peptide both at diagnosis and after 1 year, and analyzed decline in relation to clinical symptoms and signs, initial C-peptide and occurrence of auto-antibodies. RESULTS: Younger children lost more C-peptide (p<0.001) and the higher the C-peptide at diagnosis the larger the decline during the first year (p<0.0000). Patients with higher BMI had higher C-peptide at diagnosis but lost more (p<0.01), and those with lower HbA1c, without symptoms and signs at diagnosis, and with higher BMI, had higher C-peptide at diagnosis, but lost more during the first year (p<0.001). Finally, patients diagnosed during autumn had higher C-peptide at diagnosis, but lost more during the coming year (p<0.001). Occurrence of auto-antibodies did not correlate with C-peptide decline, except possibly for a more rapid loss in IAA-positive patients. CONCLUSIONS/INTERPRETATION: Even in a restricted geographical area and narrow age range (<18 years), the natural course of Type 1 diabetes is heterogeneous. This should be considered in clinical trials.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?